Physician profile
Aman Deep
NPI 1205281847
$3,479.56
in general payments reported to CMS, 2019-2025
34 companies · $880 in 2025
The $880 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.72 · 2020: $47.19 · 2021: $493 · 2022: $170 · 2023: $366 · 2024: $1,504 · 2025: $880.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,700 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,699.57 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $531.69 | 2022-2025 | Qulipta |
| Emd Serono, INC. | $393.34 | 2021-2025 | Mavenclad |
| Ucb, INC. | $261.31 | 2021-2024 | Briviact, Fintepla, Rystiggo |
| Abbott Laboratories | $199.77 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $189.13 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $185.63 | 2019-2024 | Ultomiris |
| Lilly USA, LLC | $155.70 | 2020-2025 | Amyvid, Emgality, Reyvow |
| Lundbeck LLC | $145.27 | 2023-2025 | Vyepti |
| Biogen, INC. | $141.79 | 2022-2024 | Vumerity, Tysabri |
| Eisai INC. | $126.99 | 2023-2025 | |
| Acadia Pharmaceuticals INC | $120.08 | 2023-2024 | Nuplazid |
| Neurelis, INC. | $110.07 | 2020-2025 | Valtoco |
| Novartis Pharmaceuticals Corporation | $100.32 | 2023-2024 | |
| Genentech USA, INC. | $76.24 | 2023-2024 | Ocrevus, Enspryng |
| Argenx US, INC. | $73.90 | 2024 | Vyvgart Hytrulo |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $68.38 | 2024 | |
| Celgene Corporation | $67.97 | 2021-2025 | Zeposia |
| Amneal Pharmaceuticals LLC | $66.04 | 2023-2024 | Rytary |
| Averitas Pharma INC. | $58.80 | 2025 | Qutenza |
| Teva Pharmaceuticals USA, INC. | $55.74 | 2021-2025 | Austedo Xr, Ajovy |
| Otsuka America Pharmaceutical, INC. | $48.37 | 2024 | Nuedexta |
| Mallinckrodt Hospital Products INC. | $30.93 | 2021 | |
| Amgen INC. | $30.29 | 2024 | Uplizna |
| Kyowa Kirin, INC. | $29.98 | 2021 | |
| Tanabe Pharma America, INC. | $29.23 | 2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.02 | 2022 | |
| Scilex Pharmaceuticals INC. | $23.68 | 2024 | |
| Grifols USA, LLC | $23.18 | 2024 | Gamunex-C |
| Ibsa Pharma INC. | $22.33 | 2025 | Flector, Tirosint, Licart |
| E.R. Squibb & Sons, L.L.C. | $20.92 | 2021 | |
| Adamas Pharmaceuticals, INC. | $19.86 | 2021 | |
| Harmony Biosciences LLC | $19.14 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.74 | 2020 | |
| Alnylam Pharmaceuticals INC. | $13.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aman Deep listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.